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Eighteen isolates of a nonchromogenic, slowly growing, non-tuberculous species of the genus
Mycobacterium were cultured from respiratory specimens obtained over the last eight years from
17 patients in the Netherlands. These isolates were grouped because they revealed a unique 16S
rRNA gene sequence and were related toMycobacterium xenopi. None of the 17 patients met the
American Thoracic Society diagnostic criteria for non-tuberculous mycobacterial disease, which
distinguishes the novel isolates from the related species, M. xenopi. A polyphasic taxonomic
approach, including identification by biochemical and phenotypical analysis, hsp65 gene
sequencing and PCR restriction enzyme pattern analysis, and sequence analyses of the rpoB
gene and 16S–23S internal transcribed spacer supported the separate species status of the
novel isolates. The name Mycobacterium noviomagense sp. nov. is proposed for the novel strains.
The type strain is NLA000500338T (5DSM 45145T5CIP 109766T). A more distinctive taxonomy
of NTM is a prerequisite for the assessment of their clinical relevance.
Improved detection and identification techniques have
triggered renewed interest in non-tuberculous mycobac-
teria (NTM) and their role as opportunistic pathogens.
PCR techniques and 16S rRNA gene sequence analysis have
brought to light a series of novel NTM species, however,
the clinical relevance of these species is not always clear
(Tortoli, 2003; Tortoli et al., 2001; Griffith et al., 2007).
NTM infections present predominantly as chronic pulmo-
nary disease, although extrapulmonary and disseminated
infections have also been described (Griffith et al., 2007).
Local immunosuppression due to pre-existing pulmonary
disease and systemic immunosuppression, e.g. in haema-
tological malignancy, immunosuppressive medication and
HIV/AIDS, have been identified as predisposing factors
(Griffith et al., 2007) for NTM infections. Infection has to
be differentiated from contamination and pseudo-infec-
tion, characterized by the recovery of single NTM isolates
from the respiratory or digestive tract without signs
of disease (Griffith et al., 2007; Portaels, 1995). Their
ubiquitous presence in the environment, survival in
flowing water systems and resistance to disinfectants
implies that NTM often represent laboratory or medical
equipment contamination (Griffith et al., 2007; Portaels,
1995; van Klingeren & Pullen, 1993). The diagnostic
criteria proposed in a Statement by the American Thoracic
Society (ATS) are designed to differentiate between true
infection and pseudo-infection or contamination, based on
clinical, radiological and microbiological features (Griffith
et al., 2007).
This study describes the grouping of 18 previously
unknown Mycobacterium isolates with identical 16S
rRNA gene sequences and with a high degree of gene
sequence similarity to strains of Mycobacterium xenopi. As
other features of these novel strains were highly distinct
Abbreviations: ATS, American Thoracic Society; ITS, internal transcribed
spacer; NTM, non-tuberculous mycobacteria.
The GenBank/EMBL/DDBJ accession numbers 16S rRNA, 16S–23S
ITS 1 and 2, hsp65 and rpoB gene sequences of strain
NLA000500338T are EU239955, EU439248, EU439249,
EU600390 and EU810775, respectively
Phylogenetic trees based on hsp65 and rpoB gene sequences of
selected mycobacterial species are available as supplementary material
with the online version of this paper.
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from M. xenopi and the clinical relevance differed
significantly between the new isolates and M. xenopi, the
18 isolates are proposed to represent a novel species of the
genus Mycobacterium.
The 18 novel isolates were acquired from pulmonary
samples (13 from sputum, 4 from broncho-alveolar lavage
fluid and 1 from a post-mortem lung biopsy) of 17 patients
in the Netherlands between January 1999 and January
2007. To determine clinical relevance, we examined the
medical records of all 17 patients; their baseline character-
istics are displayed in Table 1. The predominance of male
patients, mean age and history of chronic pulmonary
disease are comparable with previous NTM studies
(Griffith et al., 2007; Henry et al., 2004). None of the
patients had clinical and radiographic features suggestive of
mycobacterial lung disease; one was systemically immuno-
compromised due to HIV co-infection. The post-mortem
lung biopsy sample showed histological features of
bronchopneumonia and invading bacteria, without fea-
tures of mycobacterial disease such as granuloma forma-
tion. All patient samples were negative for acid-fast bacilli
on direct microscopy which suggested the presence of a low
number of NTM in the original sample or contamination
after sample division for culture and microscopy. Although
follow-up sputum cultures were performed for 16 patients,
only one patient produced another culture that was
positive for the novel strains. All others had a single
positive culture. Based on these findings, none of the
patients from whom the novel strains were isolated met the
ATS criteria for pulmonary NTM disease (Griffith et al.,
2007). Good clinical response to non-antimycobacterial
regimes, the subsequent establishment of alternative
diagnoses and the observed spontaneous conversion to
negative cultures suggested that the novel strains were not
the causative agent of these patients’ symptoms. The novel
strains therefore seem to have no clinical relevance, which
distinguishes them from phylogenetically related, but more
pathogenic species such as M. xenopi and Mycobacterium
heckeshornense (Griffith et al., 2007; Roth et al., 2000; van
Ingen et al., 2008).
Two patients received antituberculosis treatment for an
average period of 10 weeks, after a presumptive diagnosis
of TB. Treatment of patients not meeting the ATS
diagnostic criteria is potentially harmful to patients in
terms of adverse effects and costs (van Crevel et al., 2001).
Geographical clustering of the patients was observed,
favouring the south-east of the Netherlands, in adjacent
areas of the Limburg (7 cases), Gelderland (5 cases) and
Noord-Brabant (2 cases) provinces. This clustering sug-
gested the presence of the novel strains in specific local
environments or tap water. Since the clustering was seen
geographically, but not over time, contamination from
medical machinery or the laboratories involved seemed less
likely.
All of the novel isolates were subjected to laboratory
diagnosis by the National Mycobacteria Reference
Laboratory of the National Institute for Public Health
and the Environment (RIVM). The RIVM provides
molecular identification, drug susceptibility testing and
epidemiological typing of mycobacterial isolates for all
healthcare institutions in the Netherlands.
Biochemical identification and HPLC analysis of cell-wall
mycolic acid content were performed using previously
described approaches (Le´vy-Fre´bault & Portaels, 1992;
Centers for Disease Control and Prevention, 1996). Eight
isolates (4 M. xenopi, 4 of the novel strains) were subjected
to biochemical testing. The results are detailed in Table 2.
Morphologically, two patterns were clearly discernible. On
Middlebrook 7H10 media, the M. xenopi isolates were
scotochromogenic, showing yellow pigmentation, whereas
Table 1. Characteristics of the patients in the study group
The total number of patients was 17. COPD, Chronic obstructive
pulmonary disease.
Characteristic No. of patients
Male 13 (77%)
Mean age (yr) (range) 53 (29–86)
Dutch origin 16 (94%)
Pre-existing pulmonary disease 15 (88%)
COPD 8 (47%)
Lung cancer 4 (24%)
Healed tuberculosis 2 (12%)
Recurrent pulmonary infection* 3 (18%)
Bronchiectasis 2 (12%)
Current smoker 5 (29%)
Past smoker 3 (18%)
Alcohol abuse 3 (18%)
HIV infection 1 (6%)
*.3 In 6 months prior to sampling.
Table 2. Biochemical identification results for the novel
isolates and closely related species
Taxa: 1, M. noviomagense sp. nov.; 2, M. xenopi; 3, M. heckeshornense
(data from Roth et al., 2000); 4, M. botniense (Torkko et al., 2000).
None of the taxa were able to tolerate 5% NaCl in Lowenstein–Jensen
(LJ) medium. +, Positive; 2, negative; V, variable; NC, nonchromo-
genic; SC, scotochromogenic; NP, not published.
Characteristic 1 2 3 4
Growth at 45 uC 2 + + +
Morphology NC SC SC SC
Colony size Small Large NP Small
Tolerance to (in LJ medium):
Isoniazid 10 mg ml21 2 2 2 NP
Thiophene 2-carboxylic acid + + NP NP
Hydroxylamine 250 mg ml21 V + NP NP
Para-nitrobenzoate 500 mg ml21 + V NP NP
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colonies of the novel species were smaller and nonchromo-
genic. All M. xenopi isolates grew at 45 uC, as previously
reported (Torkko et al., 2000), but the novel strains were
unable to grow at this temperature (Table 2). Biochemically,
the novel isolates were indistinguishable from the cluster
comprising M. xenopi, Mycobacterium botniense and M.
heckeshornense, with negative results for urease, Tween 80
hydrolysis, niacin production, nitrate reductase, acid
phosphatase and semi-quantitative catalase. HPLC of the
novel isolates revealed a pattern characterized by one early
and one late cluster of peaks, a profile similar to that of M.
xenopi, M. heckeshornense and M. botniense (Fig. 1). The
HPLC mycobacterium library (available online at http://
www.MycobacToscana.it) was used for this comparison.
Susceptibility testing was performed for eleven of the novel
isolates from eleven patients using the agar dilution
method (van Klingeren et al., 2007). For the novel isolates,
we recorded in vitro resistance to rifampicin (MIC
2 mg l21), resistance or intermediate susceptibility to
ethambutol (MIC 10–20 mg l21) and intermediate sus-
ceptibility to isoniazid (MIC 0.5–1 mg l21). The novel
species proved susceptible in vitro to streptomycin,
cycloserine, prothionamide, amikacin, ciprofloxacin, clo-
fazimine, clarithromycin and rifabutin. The drug suscept-
ibility pattern for the novel isolates differed slightly from
clinical isolates of M. xenopi tested at RIVM which were
mostly susceptible, in vitro, to rifampicin (MIC 0.5–
1 mg l21). These results for M. xenopi are in accordance
with previous reports (Dauendorffer et al., 2002).
For molecular identification, sequencing of the full 16S rRNA
gene and 16S–23S internal transcribed spacer (ITS), partial
rpoB and hsp65 genes, and PCR restriction enzyme pattern
analysis (PRA) of the hsp65 gene were performed using
previously described methods (Kim et al., 1999; Roth et al.,
1998; Springer et al., 1996; Telenti et al., 1993). The sequences
obtained were compared with the GenBank/EMBL (NCBI,
http://www.ncbi.nlm.nih.gov) gene sequence databases.
The full 16S rRNA gene sequence for the novel species showed
96% sequence similarity with that ofM. xenopi and was 97%
similar to those of M. heckeshornense and Mycobacterium
shimoidei. A sequence difference of 1% has been proposed in
the literature as the threshold for the designation of a novel
species (Hall et al., 2003; Tortoli, 2003).
The full 16S rRNA gene sequence of the novel strains was
aligned with those of reference strains of the closest related
mycobacteria using CLUSTAL_X software (Thompson et al.,
1997). The resulting topology and tree, inferred by
neighbour-joining and visualized using the LOFT software
package (van der Heijden et al., 2007) were evaluated by
bootstrap analyses based on 1000 resamplings (Fig. 2).
Analysing only the hypervariable region A of the 16S rRNA
gene (151 bp), we found a 100% match in the GenBank/
EMBL database to a strain designated ‘most closely
resembling M. xenopi’, as reported by Hall et al. (2003).
Analysis of the phenotypic and genetic characteristics of the
novel species (Table 2, Figs 1, 2 and 3) demonstrates that
very subtle 16S rRNA gene sequence differences can be
associated with extensive divergence from the closest
related species. This brings into question the use of
monophasic identification methods.
Analysis of the 16S–23S ITS region revealed mixed
sequence patterns for all 18 novel isolates, even from
single colony cultures, and necessitated cloning. For
cloning of the ITS, amplicons were generated using primers
provided with the INNO LiPA Mycobacteria v2 kit
(Innogenetics), and cloned in the PGEM-T Easy vector
(Promega) according to the manufacturer’s instructions.
Thirty colonies of transformed Escherichia coli strain DH5F
were picked for each sample, cultured and used to prepare
plasmid DNA using the QIAprep 96 Turbo BioRobot kit
(Qiagen). For sequencing of the ITS region cloned into the
pGEM-T vector, the universal vector primers M13(221)
and M13rev were used on the plasmid preparation as
target. Cloning resulted in the recognition of two distinct
copies of the ITS, both with ,68% sequence similarity to
M. xenopi. A 93% sequence similarity was noted between
the two ITS copies. The presence of multiple copies of the
16S–23S ITS region, thus possibly multiple rRNA operons,
Fig. 1. Mycolic acid patterns of Mycobacte-
rium noviomagense sp. nov. obtained by
HPLC analysis. One early and one late cluster
of peaks are present, similar to M. xenopi. The
first (left) and last (right) peaks are the low and
high weight molecular standards.
Mycobacterium noviomagense sp. nov.
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is unexpected. This phenomenon has not been described
for M. xenopi or for closely related slow-growing NTM
species and thus supports the separate species status of the
novel isolates.
The rpoB gene sequence of the novel isolates was 95%
similar to that of the recently described species
Mycobacterium seoulense and only 92% similar to that of
M. xenopi. For the hsp65 gene sequence, the most closely
related sequences (95%) were found among members of
the Mycobacterium avium complex and Mycobacterium
branderi, with ,93% similarity to M. xenopi. The
considerable divergence in these two targets from the
otherwise related cluster comprising M. xenopi, M.
botniense and M. heckeshornense supports the separate
species status of the novel isolates. The hsp65 and rpoB gene
sequences were aligned with those of related mycobacterial
species, as for the 16S rRNA gene sequence. The resulting
topologies and trees are available as Supplementary Figs S1
and S2 (in IJSEM Online).
The hsp65 gene PRA results for the novel isolates,M. xenopi,
Mycobacterium tuberculosis H37RvT andM. botniense ATCC
700701T are shown in Fig. 3. For the novel isolates, digestion
with BstEII resulted in fragments of 240/120/100 bp,
digestion with HaeIII gave fragments of 130/10/70/45 bp.
A PRAsite (http://app.chuv.ch/prasite/index.html) compar-
ison showed this to be a unique fragment length
combination. Isolates of M. xenopi and M. tuberculosis
tested simultaneously were correctly identified using the
PRAsite database; no entry was found for M. botniense.
Description of Mycobacterium noviomagense
sp. nov.
Mycobacterium noviomagense (no.vi.o.ma.gen9se. N.L.
neut. adj. pertaining to Noviomagus, the Roman name of
Fig. 2. Phylogenetic relationship of the type
strain of the novel species, M. noviomagense
sp. nov., and related species of the genus
Mycobacterium, based on 16S rRNA gene
sequences. The neighbour-joining tree was
created and bootstrapped 1000 times with
CLUSTAL_X (Thompson et al., 1997) and visual-
ized with LOFT (Levels of Orthology through
Phylogenetic Trees; van der Heijden et al.,
2007). Bootstrap values are indicated at the
nodes.
Fig. 3. PRA typing results for the hsp65 gene. Different fragment length patterns are observed for M. botniense (lane 1), M.
xenopi (lanes 2–5), M. tuberculosis H37RvT (lane 6) and strain NLA000500338T (M. noviomagense sp. nov.; lanes 7–10).
J. van Ingen and others
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the major city in the endemic region in the Netherlands
and the location of the reference hospital; current name:
Nijmegen).
Acid-fast and Gram-positive rods. Colonies are nonchro-
mogenic and appear after 4 weeks of culture at 37 uC, no
growth occurs at 45 uC. Negative in tests for urease, Tween
80 hydrolysis, niacin production, nitrate reductase, acid
phosphatase and semi-quantitative catalase. Can be readily
identified by its unique rRNA gene sequences.
The type strain, NLA000500338T (5DSM 45145T5CIP
109766T), was recovered from sputum.
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